Evidence map›Paper›PMID 39310095›Full record

ArticleTheranostics2024

Theranostics with somatostatin receptor antagonists in SCLC: Correlation of

Ilektra Antonia Mavroeidi, Anna Romanowicz, Tristan Haake, Johannes Wienker, Martin Metzenmacher, Kaid Darwiche, Filiz Oezkan, Servet Bölükbas, Martin Stuschke, Lale Umutlu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Malignancy Detection Rates of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ilektra Antonia MavroeidiDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Anna RomanowiczGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Tristan HaakeInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Johannes WienkerDepartment of Pulmonary Medicine, Section of Interventional Pulmonology, West German Cancer Center (WTZ), University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Martin MetzenmacherDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Kaid DarwicheDepartment of Pulmonary Medicine, Section of Interventional Pulmonology, West German Cancer Center (WTZ), University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Filiz OezkanDepartment of Pulmonary Medicine, Section of Interventional Pulmonology, West German Cancer Center (WTZ), University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Servet BölükbasNational Center for Tumor Diseases (NCT) West, Essen, Germany.
Martin StuschkeGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Lale UmutluGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Marcel OpitzGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Michael NaderGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Rainer HamacherDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Jens SivekeDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Jane WinanteaDepartment of Pulmonary Medicine, Section of Interventional Pulmonology, West German Cancer Center (WTZ), University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Wolfgang P FendlerGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Marcel WieswegDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wilfried E E EberhardtDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ken HerrmannGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Dirk TheegartenInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Martin SchulerDepartment of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Hubertus HautzelGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
David KerstingGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ImmunohistochemistryLung NeoplasmsPositron Emission Tomography Computed TomographyReceptors, SomatostatinSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleGallium RadioisotopesHumansMaleMiddle AgedPositron-Emission TomographyPrognosisRadiopharmaceuticalsGallium RadioisotopesRadiopharmaceuticalsReceptors, SomatostatinSomatostatinSSTR2 protein, human68Ga-SSO120IHCPETSCLCSSTR

Identifiers

PMID39310095
PMCPMC11413793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.